BeiGene Valuation

Q: What is the Fair Price of 6160 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

6160 (HK$131.8) is trading below our estimate of [[fair value]] (HK$191.94)

Is 6160 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6160 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6160 (HK$131.8) is trading below our estimate of fair value (HK$191.94)

Significantly Below Fair Value: 6160 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6160?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 6160. This is calculated by dividing 6160's market cap by their current preferred multiple.
What is 6160's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$22.55b

6160 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.8x
Enterprise Value/EBITDA	-26.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6160's PS Ratio compare to its peers?

The above table shows the PS ratio for 6160 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	15.4x
1801 Innovent Biologics	9.3x	22.1%	HK$76.0b
9926 Akeso	29.2x	33.5%	HK$59.9b
6990 Sichuan Kelun-Biotech Biopharmaceutical	20.9x	24.7%	HK$43.0b
2696 Shanghai Henlius Biotech	2x	10.4%	HK$12.2b
6160 BeiGene	7.3x	19.1%	HK$22.6b

Price-To-Sales vs Peers: 6160 is good value based on its Price-To-Sales Ratio (7.3x) compared to the peer average (15.4x).

Price to Earnings Ratio vs Industry

How does 6160's PE Ratio compare vs other companies in the HK Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	40.3%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	40.3%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 6160 is good value based on its Price-To-Sales Ratio (7.3x) compared to the Hong Kong Biotechs industry average (11.2x).

Price to Sales Ratio vs Fair Ratio

What is 6160's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6160 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	7.3x
Fair PS Ratio	8.8x

Price-To-Sales vs Fair Ratio: 6160 is good value based on its Price-To-Sales Ratio (7.3x) compared to the estimated Fair Price-To-Sales Ratio (8.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.